APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

mRNA Cancer Vaccines and Therapeutics

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Selected research

Market Analysis & Forecast

Global mRNA Cancer Vaccines and Therapeutics Market Analysis and Forecast 2026-2032

Report ID 173894890222 December 2025199 pages

Choose your research edition.

Industry ResearchmRNA Cancer Vaccines and Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Cancer Vaccines and Therapeutics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal mRNA Cancer Vaccines and Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Cancer Vaccines and Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Cancer Vaccines and Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.

The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.

Read the full market overview

Report Includes

This report presents an overview of global market for mRNA Cancer Vaccines and Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of mRNA Cancer Vaccines and Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Cancer Vaccines and Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the mRNA Cancer Vaccines and Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global mRNA Cancer Vaccines and Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for mRNA Cancer Vaccines and Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

mRNA Cancer Vaccines and Therapeutics Segment by Company

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

mRNA Cancer Vaccines and Therapeutics Segment by Type

Adeno Carcinomas

Mucinous Carcinomas

Adenosquamous Carcinomas

mRNA Cancer Vaccines and Therapeutics Segment by Application

Infectious Disease

Cancer

Others

mRNA Cancer Vaccines and Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Adeno Carcinomas Major Player Table 3. Mucinous Carcinomas Major Player Table 4. Adenosquamous Carcinomas Major Player Table 5. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Infectious Disease Major Player Table 7. Cancer Major Player Table 8. Others Major Player Table 9. mRNA Cancer Vaccines and Therapeutics Industry Trends Table 10. mRNA Cancer Vaccines and Therapeutics Industry Drivers Table 11. mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges Table 12. mRNA Cancer Vaccines and Therapeutics Industry Restraints Table 13. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global mRNA Cancer Vaccines and Therapeutics Market Share by Region (2021-2026) Table 16. Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global mRNA Cancer Vaccines and Therapeutics Market Share by Region (2027-2032) Table 18. Global mRNA Cancer Vaccines and Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Players (2021-2026) Table 20. Global mRNA Cancer Vaccines and Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global mRNA Cancer Vaccines and Therapeutics Key Players Headquarters & Area Served Table 22. Global mRNA Cancer Vaccines and Therapeutics Players, Product Type & Application Table 23. Global mRNA Cancer Vaccines and Therapeutics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global mRNA Cancer Vaccines and Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Moderna Therapeutics Company Information Table 37. Moderna Therapeutics Business Overview Table 38. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 40. Moderna Therapeutics Recent Development Table 41. CureVac Company Information Table 42. CureVac Business Overview Table 43. CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 45. CureVac Recent Development Table 46. Translate Bio Company Information Table 47. Translate Bio Business Overview Table 48. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 50. Translate Bio Recent Development Table 51. BioNTech Company Information Table 52. BioNTech Business Overview Table 53. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 55. BioNTech Recent Development Table 56. Sangamo Therapeutics Company Information Table 57. Sangamo Therapeutics Business Overview Table 58. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 60. Sangamo Therapeutics Recent Development Table 61. Argos Therapeutics Company Information Table 62. Argos Therapeutics Business Overview Table 63. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 65. Argos Therapeutics Recent Development Table 66. In-Cell-Art Company Information Table 67. In-Cell-Art Business Overview Table 68. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 70. In-Cell-Art Recent Development Table 71. eTheRNA Company Information Table 72. eTheRNA Business Overview Table 73. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 75. eTheRNA Recent Development Table 76. Ethris Company Information Table 77. Ethris Business Overview Table 78. Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 80. Ethris Recent Development Table 81. Tiba Biotechnology Company Information Table 82. Tiba Biotechnology Business Overview Table 83. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 85. Tiba Biotechnology Recent Development Table 86. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 87. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 88. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 89. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 90. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 92. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 100. China mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 101. China mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 102. China mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 103. China mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia mRNA Cancer Vaccines and Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. mRNA Cancer Vaccines and Therapeutics Image Figure 2. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Cancer Vaccines and Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Adeno Carcinomas Image Figure 5. Mucinous Carcinomas Image Figure 6. Adenosquamous Carcinomas Image Figure 7. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global mRNA Cancer Vaccines and Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Infectious Disease Image Figure 10. Cancer Image Figure 11. Others Image Figure 12. Global mRNA Cancer Vaccines and Therapeutics Market Size (US$ Million) & (2021-2032) Figure 13. Global mRNA Cancer Vaccines and Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global mRNA Cancer Vaccines and Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global mRNA Cancer Vaccines and Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032) Figure 25. North America mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032) Figure 26. North America mRNA Cancer Vaccines and Therapeutics Revenue Share by Country (2021-2032) Figure 27. United States mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032) Figure 32. Europe mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032) Figure 33. Europe mRNA Cancer Vaccines and Therapeutics Revenue Share by Country (2021-2032) Figure 34. Germany mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032) Figure 44. China mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032) Figure 45. Asia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032) Figure 47. Asia mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia mRNA Cancer Vaccines and Therapeutics Revenue Share by Region (2021-2032) Figure 49. Japan mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032) Figure 57. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032) Figure 58. SAMEA mRNA Cancer Vaccines and Therapeutics Revenue Share by Country (2021-2032) Figure 59. Brazil mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt mRNA Cancer Vaccines and Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno Carcinomas
  • Mucinous Carcinomas
  • Adenosquamous Carcinomas
Applications
  • Infectious Disease
  • Cancer
  • Others
Companies covered
  • Moderna Therapeutics
  • CureVac
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 mRNA Cancer Vaccines and Therapeutics Market by Type
  3. 1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Adeno Carcinomas
  5. 1.2.3 Mucinous Carcinomas
  6. 1.2.4 Adenosquamous Carcinomas
  7. 1.3 mRNA Cancer Vaccines and Therapeutics Market by Application
  8. 1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Infectious Disease
  10. 1.3.3 Cancer
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 mRNA Cancer Vaccines and Therapeutics Market Dynamics
  1. 2.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
  2. 2.2 mRNA Cancer Vaccines and Therapeutics Industry Drivers
  3. 2.3 mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges
  4. 2.4 mRNA Cancer Vaccines and Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global mRNA Cancer Vaccines and Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global mRNA Cancer Vaccines and Therapeutics Growth Trends by Region
  3. 3.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Players
  2. 4.1.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global mRNA Cancer Vaccines and Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global mRNA Cancer Vaccines and Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global mRNA Cancer Vaccines and Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global mRNA Cancer Vaccines and Therapeutics Players, Product Type & Application
  8. 4.5 Global mRNA Cancer Vaccines and Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global mRNA Cancer Vaccines and Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 mRNA Cancer Vaccines and Therapeutics Tier 1, Tier 2, and Tier 3
5 mRNA Cancer Vaccines and Therapeutics Market Size by Type
  1. 5.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2021-2032)
6 mRNA Cancer Vaccines and Therapeutics Market Size by Application
  1. 6.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Moderna Therapeutics
  2. 7.1.1 Moderna Therapeutics Company Information
  3. 7.1.2 Moderna Therapeutics Business Overview
  4. 7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  6. 7.1.5 Moderna Therapeutics Recent Developments
  7. 7.2 CureVac
  8. 7.2.1 CureVac Company Information
  9. 7.2.2 CureVac Business Overview
  10. 7.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
  12. 7.2.5 CureVac Recent Developments
  13. 7.3 Translate Bio
  14. 7.3.1 Translate Bio Company Information
  15. 7.3.2 Translate Bio Business Overview
  16. 7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
  18. 7.3.5 Translate Bio Recent Developments
  19. 7.4 BioNTech
  20. 7.4.1 BioNTech Company Information
  21. 7.4.2 BioNTech Business Overview
  22. 7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
  24. 7.4.5 BioNTech Recent Developments
  25. 7.5 Sangamo Therapeutics
  26. 7.5.1 Sangamo Therapeutics Company Information
  27. 7.5.2 Sangamo Therapeutics Business Overview
  28. 7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  30. 7.5.5 Sangamo Therapeutics Recent Developments
  31. 7.6 Argos Therapeutics
  32. 7.6.1 Argos Therapeutics Company Information
  33. 7.6.2 Argos Therapeutics Business Overview
  34. 7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  36. 7.6.5 Argos Therapeutics Recent Developments
  37. 7.7 In-Cell-Art
  38. 7.7.1 In-Cell-Art Company Information
  39. 7.7.2 In-Cell-Art Business Overview
  40. 7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
  42. 7.7.5 In-Cell-Art Recent Developments
  43. 7.8 eTheRNA
  44. 7.8.1 eTheRNA Company Information
  45. 7.8.2 eTheRNA Business Overview
  46. 7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
  48. 7.8.5 eTheRNA Recent Developments
  49. 7.9 Ethris
  50. 7.9.1 Ethris Company Information
  51. 7.9.2 Ethris Business Overview
  52. 7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
  54. 7.9.5 Ethris Recent Developments
  55. 7.10 Tiba Biotechnology
  56. 7.10.1 Tiba Biotechnology Company Information
  57. 7.10.2 Tiba Biotechnology Business Overview
  58. 7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
  60. 7.10.5 Tiba Biotechnology Recent Developments
8 North America
  1. 8.1 North America mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
  2. 8.2 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America mRNA Cancer Vaccines and Therapeutics Revenue by Country
  11. 8.6.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
  2. 9.2 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country
  11. 9.6.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
  2. 10.2 China mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
  2. 11.2 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Country
  11. 11.6.1 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia mRNA Cancer Vaccines and Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country
  11. 12.6.1 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA mRNA Cancer Vaccines and Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst